To evaluate the efficacy of SORT system-based therapy, 4T1 tumor-bearing mice were administered with PBS, VNP, VNPCon-IL2, or VNPSORT-IL2via tail vein 10 days post-tumor inoculation. This evidence concerns the gene IL2 and neoplasm.